Mitochondrial fragmentation and network architecture in degenerative diseases

Syed I. Shah, Johanna G. Paine, Carlos Perez, Ghanim Ullah

Department of Physics, University of South Florida, Tampa, FL, United States of America

Abstract

Fragmentation of mitochondrial network has been implicated in many neurodegenerative, renal, and metabolic diseases. However, a quantitative measure of the microscopic parameters resulting in the impaired balance between fission and fusion of mitochondria and consequently the fragmented networks in a wide range of pathological conditions does not exist. Here we present a comprehensive analysis of mitochondrial networks in cells with Alzheimer's disease (AD), Huntington's disease (HD), amyotrophic lateral sclerosis (ALS), Parkinson's disease (PD), optic neuropathy (OPA), diabetes/cancer, acute kidney injury, Ca\(^{2+}\) overload, and Down Syndrome (DS) pathologies that indicates significant network fragmentation in all these conditions. Furthermore, we found key differences in the way the microscopic rates of fission and fusion are affected in different conditions. The observed fragmentation in cells with AD, HD, DS, kidney injury, Ca\(^{2+}\) overload, and diabetes/cancer pathologies results from the imbalance between the fission and fusion through lateral interactions, whereas that in OPA, PD, and ALS results from impaired balance between fission and fusion arising from longitudinal interactions of mitochondria. Such microscopic difference leads to major disparities in the fine structure and topology of the network that could have significant implications for the way fragmentation affects various cell functions in different diseases.

Introduction

Mitochondrion is a ubiquitous organelle and powerhouse of the cell that exists in living cells as a large tubular assembly, extending throughout the cytoplasm and in close apposition with other key organelles such as nucleus, the endoplasmic reticulum, the Golgi network, and the cytoskeleton [1–5]. Its highly flexible and dynamic network architecture ranging from a few hundred nanometers to tens of micrometers with the ability to rapidly change from fully connected to fragmented structures makes it suitable for diverse cytosolic conditions and cell functions [6–8]. Cells continuously adjust the rate of mitochondrial fission and fusion in response to changing energy and metabolic demands to facilitate the shapes and distribution of mitochondria throughout the cell [9–11]. Similarly, stressors such as reactive oxygen species (ROS) and Ca\(^{2+}\) dysregulation interfere with various aspects of mitochondrial dynamics [12–14]. This is probably why many neuronal, metabolic, and renal diseases have been linked to
primary or secondary changes in mitochondrial dynamics [9, 15–37]. Neuronal cells, due to their complex morphology and extreme energy dependent activities such as synaptic transmission, vesicle recycling, axonal transport, and ion channels and pumps activity, are particularly sensitive to changes in the topology of mitochondrial network [38–41].

The mitochondrial network organization makes a bidirectional relationship with the cell’s bioenergetics and metabolic variables [11, 42]. For example, the morphological state of mitochondria has been linked to their energy production capacity [43–46], as well as cell health and death [10, 46–49] on one hand, alterations in mitochondrial energy production caused by genetic defects in respiratory chain complexes lead to fragmentation of mitochondrial network [50, 51] on the other hand. Similarly, while ROS induces fragmentation of mitochondrial network [12–14], overproduction of ROS in hyperglycemic conditions requires dynamic changes in mitochondrial morphology and fragmentation of the network [52]. Furthermore, high cytosolic Ca\(^{2+}\) induces mitochondrial fragmentation [14], whereas fragmentation blocks the propagation of toxic intracellular Ca\(^{2+}\) signals [53, 54] and can limit the local Ca\(^{2+}\) uptake capacity of mitochondria due to their smaller sizes. Thus dynamic changes in mitochondrial morphology and fragmentation of its network can be part of the cycle that drives the progression of degenerative diseases [11–13, 18, 22, 52, 55–70].

Despite a clear association with many cell functions in physiological conditions, quantitative measures of the microscopic fission and fusion rates leading to a given topology of the mitochondrial network remain elusive. While fluorescence imagining has been instrumental in providing biologically useful insights into the structure and function of mitochondria, detailed description of the kinetics and the dynamical evolution of the complex mitochondrial networks in health and disease are still out of reach of these techniques. Although it is difficult to study such dynamics experimentally, computational techniques provide a viable alternative. Various computational studies on the identification and analysis of network parameters from experimental mitochondrial micrographs have been performed using either custom built applications [71–76] or commercially available tools [77], depending upon the particular question being asked. However, a comprehensive study quantifying the imbalance between fission and fusion responsible for the network fragmentation observed in many diseases does not exist.

In this paper, we adopt and extend the method developed in Refs. [75, 76] using a pipeline of computational tools that process and extract a range of network parameters from mitochondrial micrographs recorded through fluorescence microscopy, and simulate mitochondrial networks to determine microscopic rates of fission and fusion leading to the observed network properties. We first demonstrate our approach by application to images of mitochondrial networks in striatal cells from YAC128 Huntington’s disease (HD) transgenic mice (bearing a 111 polyglutamine repeat Q111/0 and Q111/1) and their control counterparts reported in Ref. [78]. This is followed by the application of our technique to images of mitochondria in cells with Alzheimer’s disease (AD) [79], amyotrophic lateral sclerosis (ALS) [80], Parkinson’s disease (PD) [81], optic neuropathy (OPA) [66], diabetes/cancer [65], acute kidney injury [64], Ca\(^{2+}\) overload [14], and Down syndrome (DS) [36, 82] pathologies from the literature. The images analyzed in this study were selected based on the following criteria. (1) The paper from which the images were selected reported images of mitochondrial networks both in normal and diseased cells from the same cell/animal model. (2) The images were of high enough quality so that they can be processed properly, making sure that the network extracted indeed represented the actual mitochondrial network without introducing artifacts during the processing. The cell/animal models used in these studies are listed in S1 Table in the Supplementary Information Text and detailed in the Results section below. Although we found fragmented mitochondrial networks and imbalanced fission and fusion in all these pathologies
in comparison to their respective control conditions, significant differences between the microscopic properties underlying such fragmentation exist in different diseases.

Methods

Image analysis

Mitochondria in a cell can form networks of different topologies ranging from a fully disintegrated network with one mitochondrion per cluster to a well-connected network comprising of clusters with several mitochondria per cluster to a fully connected network where all clusters are connected to form a single giant cluster. These topologies can be uniquely distinguished by various network parameters such as the mean degree $<k>$ (the average number of nearest neighbors), giant cluster $N_g$ (the largest cluster in the network), giant cluster normalized with respect to the total number of nodes (mitochondria) or edges (connections) $N_g/N$, and distributions of various features such as the number of mitochondria in various linear branches, cyclic loops, and clusters comprising both branches and loops.

To extract all this information from experimental images of mitochondrial networks, we adopt and extend the procedure first reported in Ref. [75] using a pipeline of Matlab (The MathWorks, Natick, MA) tools. Often, we are required to preprocess the images for removing any legends or masking/removing areas that contain artifacts (Fig 1A). The colors representing processes other than mitochondria are removed and the resulting image is converted to grayscale image (Fig 1B). Next, we take a series of steps to extract the underlying mitochondrial network and the key information about the network.

Fig 1. Steps involved in the processing of the images and retrieval of various network features. (a) Original image, (b) the grayscale image containing mitochondrial network only, (c) binary image, and (d) skeletonized image. Panel (e) shows a graph (partially shown) representation of the skeletonized image where red, green, and blue colors represent nodes with degree 1, 2 and 3 respectively. Size distribution of cyclic loops (f) and linear branch lengths (g), and cumulative probability distribution of cluster sizes (h) in mitochondrial network in striatal cells from wildtype (NL, red) and YAC128 HD (blue) transgenic mice. The image used for the mitochondrial network extraction in panel (a) was adopted from Ref. [78] with permission.

https://doi.org/10.1371/journal.pone.0223014.g001
Step 1: We use Matlab function `im2bw` to generate a binary image (Fig 1C) from the preprocessed gray scale image (Fig 1B) of the micrograph by applying appropriate threshold intensity using Matlab function `graythresh`.

Step 2: The resulting binary image is reduced to a trace of one-pixel thick lines called skeleton using Matlab function `bwmorph`, which represents mitochondrial network (Fig 1D).

Step 3: To extract various features of the mitochondrial network from skeletonized image, we first label different clusters using Matlab routine `bwlabel`. The labeled clusters are then converted to a graph (Fig 1R, only partial graph is shown for clarity) where the nodes are color-coded according to their degree. The graph is then used to extract network parameters such as $<k>$, $N_g$, and $N_g/N$. We also extracted size distribution of loops or cycles with no open ends (Fig 1F), size distribution of branches with at least one open end (Fig 1G), and cumulative probability distribution of individual cluster sizes (Fig 1H) in terms of number of edges, where a single cluster could have both loops and branches and is disconnected from other clusters.

All the above properties are extracted for mitochondrial networks in the cells with different pathologies and the corresponding control cells for comparison. For example, we compare the size distributions of loops, branches, and clusters in striatal cells from YAC128 Huntington’s disease (HD) transgenic mice (blue) and their control counterparts (NL, red) reported in Ref. [78] in Fig 1F–1H. A clear leftward shift in these distributions can be seen in HD, indicating a fragmented mitochondrial network as compared to NL cells. The overall number of loops and branches also decreases in HD.

**Modeling and simulating mitochondrial network**

To simulate mitochondrial network, we used the model described in Sukhorukov et al. [76], where the network results from two fusion and two fission reactions (Fig 2). In the model, a dimer tip representing a single mitochondrion can fuse with other dimer tips, forming a network node. At most three tips can merge. The two possible fusion and corresponding fission reactions are termed as tip-to-tip and tip-to-side reactions. The biological equivalent of the tip-to-tip reaction would be the fusion of two mitochondria moving along the same microtubule track in the opposite directions and interacting longitudinally [83]. Similarly, tip-to-side reaction mimics the merging of two mitochondria moving laterally [83]. These two types of
interactions are explained further in section “Mitochondrial interactions” of Supplementary Information text and sketched in S1 Fig. This way, the network can have nodes with degree 1 (isolated tip), degree 2 (two merged nodes), and degree 3 (three merged nodes). To each fusion process, there is an associated fission process. Thus, the four possible processes can be represented by the following two reaction equations.

\[ \text{X}_1 + \text{X}_1 \xrightarrow{a_1/b_1} \text{X}_2, \]

\[ \text{X}_1 + \text{X}_2 \xrightarrow{a_2/b_2} \text{X}_3. \]

Where \( \text{X}_1 \) (Fig 2A, red), \( \text{X}_2 \) (Fig 2A, green), and \( \text{X}_3 \) (Fig 2A, blue) represent nodes with degree 1, 2, and 3 respectively. Nodes with degree 4 are not included because of their extremely low probability [75, 76]. Network edges connecting the nodes define minimal (indivisible) constituents of the organelle. Therefore, all parameters are calculated in terms of number of edges in the network.

Next, we implement the model as an agent-based model using Gillespie algorithm [75, 76, 84]. We initialize the simulation with the number of edges (N) estimated from experimental micrographs of the cell that we intend to model and all nodes initially in \( \text{X}_1 \) form with their number equal to the mitochondrial components representing the cell. The number of edges in the images processed in this paper ranges from as few as 72 to as many as 19519. The network is allowed to evolve through a sequence of fusion and fission processes according to their propensities at a given time step. In all cases, we run the algorithm for 5N time steps to reach the steady state and extract various network features \(<\kappa>, N_g/N\) branch lengths etc.) at the end of the run using various Graph and Network algorithms in Matlab. Depending on the fusion (a1 & a2) and fission (b1 & b2) rates used, networks of varying properties ranging from mostly consisting of isolated mitochondria or branched clusters to a fully connected one giant cluster can be generated [76].

To search for a network with specific properties, we follow the procedure in [75, 76] and vary the ratio of fusion and fission processes, i.e. \( C_1 = a_1/b_1 \) and \( C_2 = a_2/b_2 \) by fixing \( b_1 \) and \( b_2 \) at 0.01 and 3b1/2 respectively, and allowing \( a_1 \) and \( a_2 \) to vary. For every set of \( (C_1, C_2) \) values, we repeat the simulations 100 times with different sequences of random numbers and report different parameters/features of the network averaged over all 100 runs. Results from a sample run with \( N = 3000 \) are shown in Fig 3A1–3A3, where we plot \(<k>\) (Fig 3A1) and \( N_g/N \) (Fig 3A2) as functions of \( C_2 \) at fixed \( C_1 = 0.0007 \). \( N_g/N \) versus \(<k>\) from the same simulation is shown in Fig 3A3. Increasing \( C_1 \) shifts the curve to the right. We scan a wide range of \( C_1 \) and \( C_2 \) values and plot \(<k>\) and \( N_g/N \) obtained from experimental images on this two parameter phase space diagram. As an example, the red crosses in the inset in Fig 3A3 represent \( N_g/N \) versus \(<k>\) retrieved from experimental images of mitochondria in striatal cells from NL and HD transgenic mice [78]. The values from the image are mapped with the corresponding \( C_1 \) and \( C_2 \) values on the phase space diagram and reported as the values for that cell.

Larger values of \( C_1 \) and \( C_2 \) mean more frequent tip-to-tip and tip-to-side fusion respectively, and vice versa. A very small value of \( C_2 \) (or \( C_1 \)) results in a network mainly consisting of linear chains and isolated nodes (Fig 3B1) with small \(<k>\) and \( N_g/N \) (Fig 3A1 & 3A2). Medium value of \( C_2 \) leads to a network having clusters with both branches and loops (Fig 3B2), whereas large \( C_2 \) value results in a network having one giant cluster (Fig 3B3) with large
and \( N_{g}/N \) values. To demonstrate further that how low, intermediate, and large values of \( C_2 \) (or \( C_1 \)) affect the fine structure of the network, we show distributions of the loop, branch, and cluster sizes from three simulations in Fig 3C1–3C3. We pick \( C_2 \) values obtained for mitochondrial networks in cells with HD pathology \((C_2 = 0.22\times10^{-4}, C_1 = 4.9\times10^{-4})\) [78], NL cells \((C_2 = 0.44\times10^{-4}, C_1 = 4.9\times10^{-4})\) [78], and NL cells from ALS experiments \((C_2 = 1.0\times10^{-4}, C_1 = 4.8\times10^{-4})\) reported in Ref. [80] as representatives of the three cases. We also performed simulations using \( C_1 \) and \( C_2 \) values representing mitochondrial networks in cells with DS pathology \((C_2 = 0.32\times10^{-4} \text{ value})\) and their corresponding NL cells \((C_2 = 0.88\times10^{-4} \text{ value})\) [36, 82] and observed a clear rightward shift in all three distributions at \( 0.88\times10^{-4} \) as compared to those at \( 0.32\times10^{-4} \) (not shown). In addition to shifting to the right, the range of all three distributions widens as we increase the value of \( C_2 \), indicating that both the sizes and diversity of the network components increase.

**Results**

As pointed out above, we processed images of mitochondrial networks in cells with various neurological pathologies including AD [79], ALS [80], PD [81], HD [78], OPA [66], \( \text{Ca}^{2+} \) overload in astrocytes [14], and DS [36, 82] as well as other conditions such as kidney disease [64]
and diabetes/cancer [65] from published literature. Details of the cell models analyzed are given in the following paragraphs and tabulated in S1 Table. Key network parameters such as $<k>$, $N_g$, $N_g/N$ retrieved from the diseased cells and their normal counterparts are listed in Table 1. A universal signature of all pathological conditions we analyzed in this study is that mitochondrial networks in the diseased cells are fragmented as compared to normal cells. In terms of network parameters, this translates into smaller $<k>$, average cluster size, $N_g$, and $N_g/N$ for mitochondrial networks in cells with pathological conditions as compared to control cells.

Our observations are in agreement with previous studies investigating these diseases individually. For example, it has been shown that mitochondrial dysfunction in fibroblasts from human fetuses with trisomy of Hsa21 (DS-HFF) [82], human fibroblasts from subjects with DS [36], and mouse embryonic fibroblasts derived from a DS mouse model [36] are correlated with the significant fragmentation of the underlying mitochondrial network when compared to healthy cells, in line with our results showing that $<k>$ and $N_g/N$ for the network in NL cells are higher than those in DS affected cells. Another study investigating mitochondrial dynamics in AD showed that neuroblastoma cells overexpressing APPswe mutant and amyloid β display more fragmented mitochondrial networks as compared to control cells [79]. Along similar lines, cells with HD pathology were shown to be accompanied by mitochondrial fragmentation and cristae alterations in several cellular models of the disease. These alterations were attributed to increased basal activity of the Ca$^{2+}$-dependent phosphatase calcineurin that dephosphorylates the pro-fission dynamin related protein 1 (Drp1) and mediates its translocation to mitochondria [85]. This study also showed that the upregulation of calcineurin activity results from the higher Ca$^{2+}$ concentration in the cytoplasm in HD due to enhanced release from intracellular stores such as the endoplasmic reticulum. Parkinson’s disease is another complex multifactorial etiology, involving many genetic and environmental factors over the
course of time. An in-depth analysis of the human primary skin fibroblasts obtained from sporadic late-onset PD patients with those from healthy age-matched control subjects showed that the diseased fibroblasts exhibit significantly compromised mitochondrial structure and function [81]—in line with the network parameters estimated in our study.

We also analyzed images of mitochondrial networks in mouse hippocampus-derived neuroblastsoma cells, transduced with wildtype, R15L, and S59L mutations of Coiled-coil-helix-coiled-coil-helix domain-containing protein 10 (CHCHD10) that were reported in Ref. [80]. Both $\langle k \rangle$ and $N_g$ (and $N_g/N$) decrease in the presence of CHCHD10 mutations as compared to wildtype CHCHD10. CHCHD10 mutations are associated with a spectrum of familial and sporadic frontotemporal dementia-ALS diseases [86, 87], Charcot–Marie–Tooth disease type 2 [88], mitochondrial myopathy and spinal muscular atrophy Jokela type [89]. Recently, Woo et al. [80] showed that CHCHD10 results in cytoplasmic accumulation of TAR DNA-binding protein 43 (TDP-43) that increases mitochondrial fission proteins Drp1 and Fis1, reduces mitochondrial fusion protein Mfn1, and promotes mitochondrial fragmentation [90, 91]. TDP-43 pathology is associated with the vast majority of ALS and frontotemporal lobar degenerations [92] and plays a major role in other neurodegenerative diseases [93, 94] and cellular toxicity in general [95, 96]. Overexpression of TDP-43 also promotes juxtanuclear aggregation of mitochondria [90, 91]. The larger average cluster size we observe in cells with CHCHD10 mutations as compared to NL cells could reflect this behavior (Table 1, column 6).

Mitochondrial damage is also believed to be a key contributor to renal diseases like acute kidney injury. By processing images of mitochondrial networks reported in Brooks et al. [64], we observe smaller $\langle k \rangle$ and $N_g/N$ in rat proximal tubular cells and primary renal proximal tubular cells treated with azide to induced ATP depletion and model in vivo ischemia. These values confirm the conclusions in Ref. [64], where a larger number of cells exhibited fragmented mitochondrial networks in cells treated with azide and cisplatin to induce nephrotoxicity as compared to control cells. The same study also reported that both ischemic acute kidney injury and tubular apoptosis were observed to be ameliorated by Mdivi-1, a pharmacological inhibitor of Drp1.

A dimeric mitochondrial outer membrane protein, MitoNEET, is implicated in the etiology of many pathologies including obesity, insulin resistance, diabetes, and cancer. Its downregulation reduces cell proliferation and tumor growth in breast cancer adipocytes and in pancreatic cells [97–100]. Our analysis of fluorescence images of MitoNEET knockout mouse embryonic fibroblasts indicates that $\langle k \rangle$, average cluster size, and $N_g/N$ all decrease when compared with control mouse embryonic fibroblasts. These results are in agreement with the observations suggesting that the downregulation of MitoNEET in mouse embryonic fibroblasts and pancreatic β cells results in reduced connectivity of mitochondrial network and vice versa [99, 101].

Mitochondriopathies are also associated with many multisystemic diseases including infantile-onset developmental delay, muscle weakness, ataxia, and optic nerve atrophy caused by a homozygous mutation in the yeast mitochondrial escape 1-like 1 gene (YME1L1) [102]. YME1L1 plays a key role in mitochondrial morphology by mediating optic atrophy type 1 (OPA1) protein that is involved in mitochondrial fusion and remodeling, and is also believed to be associated with hereditary Spastic Paraplegia 7 disease, Autosomal Recessive disorder, obesity, and defective thermogenesis [73, 103–106]. We found that $\langle k \rangle$, mean cluster size, and $N_g/N$ all decrease in cells expressing YME1L1 missense mutation R149W and YME1L1. These results are in agreement with the observations of fragmented mitochondrial network in HeLa cells and fibroblasts from mouse and patients with proliferation defect expressing R149W or YME1L1 knockout cells [66] and SHSY5Y cells where YME1L1 is degraded in response to distinct cellular stresses that depolarize mitochondria and deplete cellular ATP [103].
Interestingly, a common feature among the pathological conditions discussed in this paper and several other degenerative diseases where mitochondrial fragmentation is observed, is that intracellular Ca\textsuperscript{2+} concentration in the cells affected by these pathologies is upregulated [107–120]. Therefore, we analyzed images of mitochondrial networks in cells with higher intracellular Ca\textsuperscript{2+} concentration. These images were reported in Ref. [14], where rat cortical astrocytes were treated with Ca\textsuperscript{2+} ionophore 4Br-A23187 that increases intracellular Ca\textsuperscript{2+} concentration in dose-dependent manner. We found that \( \langle k \rangle \), average cluster size, \( N_g \), and \( N_g/N \) for mitochondrial network in astrocytes exposed to 4Br-A23187 are significantly lower than those observed in control cells.

Next, we perform extensive stochastic simulations (see “Modeling and simulating mitochondrial network” section) to search for the tip-to-tip and tip-to-side fusion and fission rates characterizing mitochondrial networks in cells with different pathologies and their respective control conditions. Final results from these simulations are summarized in Table 2. As is evident from columns 7 and 8, in all cases the values of \( C_1 \) or/and \( C_2 \) for mitochondrial network in diseased cells are smaller than those in control cells. This confirms the lower tip-to-tip or tip-to-side fusion to fission ratios in the diseased cells.

In most cases, we identified \( C_1 \) and \( C_2 \) where the model gives the exact \( \langle k \rangle \) and \( N_g/N \) values observed in the experiment. In some cases, the \( N_g/N \) value from simulation is slightly different than that retrieved from experimental images. However, it is possible to get \( C_1 \) and \( C_2 \) values that would result in the exact \( N_g/N \) values. This will require running the algorithm with smaller \( C_1 \) and \( C_2 \) increments, which will significantly increase computational time. On average, simulating the network with one set of \( C_1 \) and \( C_2 \) values and 100 repetitions to minimize the stochastic variability, takes 5 to 10 hours (depending on \( N \)). Thus, halving the increments of one or both of \( C_1 \) and \( C_2 \) would double or quadruple the computational time respectively.

Table 2. Comparison of microscopic parameters of mitochondrial network obtained from simulations and experiments. Column 1 lists the condition for which images of normal (NL) and diseased cells were analyzed (column 2). Columns 3 & 4 and 5 & 6 compare \( \langle k \rangle \) and \( N_g/N \) respectively from experiment and theory. Columns 7 & 8 are the \( C_1 \) (tip-to-tip fusion/fission) and \( C_2 \) (tip-to-side fusion/fission) values obtained by fitting the model to the data and used in simulations.

| Condition             | Normal vs diseased | Mean degree \( \langle k \rangle \) | \( N_g/N \) | \( C_1 \) | \( C_2 \) |
|-----------------------|--------------------|-------------------------------------|-------------|----------|----------|
|                       | Exp Theory         | Exp Theory                          | Exp Theory  |          |          |
| HD                    | NL                 | 1.67/1.67                           | 0.0188/0.022| 4.9e-4/4.4e-5|
|                       | HD                 | 1.63/1.63                           | 0.0186/0.0101| 4.9e-4/2.2e-5|
| AD                    | NL                 | 1.64/1.64                           | 0.042/0.108 | 7.0e-4/2.3e-4|
|                       | AD                 | 1.62/1.62                           | 0.038/0.067 | 7.0e-4/1.9e-4|
| DS                    | NL                 | 1.52/1.52                           | 0.017/0.017 | 5.0e-4/0.88e-4|
|                       | DS                 | 1.47/1.47                           | 0.010/0.010 | 5.0e-4/0.32e-4|
| PD                    | NL                 | 1.72/1.72                           | 0.006/0.008 | 1.2e-3/7.0e-6|
|                       | PD                 | 1.70/1.70                           | 0.005/0.007 | 9.8e-4/7.0e-6|
| ALS                   | NL                 | 1.75/1.75                           | 0.369/0.359 | 4.8e-4/1.0e-4|
|                       | ALS                | 1.69/1.69                           | 0.222/0.225 | 1.0e-4/1.0e-4|
| Kidney injury         | NL                 | 1.66/1.66                           | 0.012/0.016 | 9.1e-4/4.0e-5|
|                       | Kidney injury      | 1.64/1.64                           | 0.011/0.011 | 9.0e-4/0.25e-4|
| Diabetes/Cancer       | NL                 | 1.67/1.67                           | 0.023/0.020 | 9.8e-4/4.5e-5|
|                       | Diabetes/Cancer    | 1.65/1.65                           | 0.010/0.013 | 9.8e-4/2.5e-5|
| OPA                   | NL                 | 1.69/1.69                           | 0.0093/0.0081| 9.0e-4/1.0e-5|
|                       | OPA                | 1.67/1.67                           | 0.0055/0.0075| 7.6e-4/1.0e-5|
| Ca\textsuperscript{2+} | NL                 | 1.59/1.59                           | 0.039/0.038 | 7.0e-4/1.46e-4|
|                       | Ca\textsuperscript{2+} overload | 1.57/1.58 | 0.032/0.032 | 7.0e-4/1.13e-4|

https://doi.org/10.1371/journal.pone.0223014.t002
A close look at the values of C1 and C2 reveals two main trends (Table 3). In case of HD, AD, DS, Ca\(^{2+}\) overload, kidney disease, and diabetes/cancer the fusion to fission ratio for the tip-to-tip reaction remains constant, while the fusion to fission ratio for the tip-to-side reaction decreases when compared to the control conditions. As shown by an example from HD (Fig 4A1–4A4), this results in smaller number of X3 species with a gain in X1 and X2 species in the diseased state (Fig 4A4 and Table 3). However, since the probability of cyclic loops depends on both X2 and X3, the large decrease in X3 and moderate increase in X2 lead to smaller cyclic loops and consequently smaller clusters in the diseased state (Fig 4A1 & 4A3). Larger number of X2 species with no change in X1 would translate into longer and/or larger number of linear branches. However, the simultaneous increase in the number of X1 species would result in shorter branches (Fig 4A2) and higher number of isolated mitochondria. A relatively smaller decrease in C2 leads to a smaller decrease in X3, and a smaller increase in X1 and X2, which would lead to smaller but larger number of linear chains. The larger number of linear chains could overcompensate for the small decrease in X3, resulting in a larger number of cyclic loops. Such behavior is demonstrated by an example using network statistics for diabetes (S2 Fig).

An opposite effect can be seen in case of OPA, PD, and ALS where C1 decreases and C2 remains constant when compared to normal cells. The lower fusion to fission ratio for the tip-to-tip reaction leads to larger and smaller number of X1 and X2 mitochondrial species respectively (Table 3). A larger decrease in C1 would lead to a larger increase in X1 and a larger decrease in X2, and consequently shorter, fewer linear chains (and larger number of isolated mitochondria) and vice versa. For example, the relatively smaller decrease in C1 in case of OPA leads to shorter linear branches (leftward shift in Fig 4B2) but the number of branches increases (taller bars) as compared to control conditions. Although the fusion to fission ratio for the tip-to-side reaction does not change, the larger number of linear chains available to make cyclic loops leads to a larger number of smaller loops (Fig 4B1). If the decrease in C1 is larger, one would see a significant decrease in the number of loops and branches (and significant increase in the number of isolated mitochondria) in addition to the leftward shift in the diseased case. Such behavior is demonstrated by an example using network statistics for PD (S3 Fig).

To see if the conclusions made above for a given disease holds when images of mitochondrial networks recorded from different cell/animal models or different experimental setup are used, we analyzed two more examples each for AD [121], PD [122], and ALS [91]. As clear from S2 Table, the results are largely consistent with our conclusions discussed above. The

Table 3. Comparison of the fusion to fission ratio for the tip-to-tip and tip-to-side reactions in the normal and diseased states predicted by the model. The subscripts n and d indicate normal and diseased states respectively. The C1 and C2 values estimated for different conditions are used to estimate the fractions of X1, X2, and X3 species in steady state and compare them with the diseased states.

| Condition          | C1n/C1d | C2n/C2d | X1n  | X2n  | X3n  | X1n/X1d | X2n/X2d | X3n/X3d |
|--------------------|---------|---------|------|------|------|---------|---------|---------|
| HD                 | 1.00    | 2.00    | 0.359| 0.562| 0.079| 0.985   | 0.948   | 1.852   |
| AD                 | 1.00    | 1.21    | 0.432| 0.429| 0.140| 0.992   | 0.969   | 1.143   |
| DS                 | 1.00    | 2.75    | 0.454| 0.502| 0.044| 0.980   | 0.939   | 17.058  |
| CA                 | 1.00    | 1.29    | 0.441| 0.459| 0.100| 0.990   | 0.969   | 1.238   |
| Kidney             | 1.01    | 1.60    | 0.344| 0.605| 0.052| 0.991   | 0.971   | 1.704   |
| Diabetes/ Cancer   | 1.00    | 1.80    | 0.334| 0.614| 0.052| 0.990   | 0.971   | 1.739   |
| OPA                | 1.18    | 1.00    | 0.292| 0.691| 0.018| 0.938   | 1.030   | 0.955   |
| PD                 | 1.22    | 1.00    | 0.260| 0.728| 0.012| 0.922   | 1.032   | 0.954   |
| ALS                | 4.80    | 1.00    | 0.341| 0.468| 0.191| 0.875   | 1.129   | 0.976   |

https://doi.org/10.1371/journal.pone.0223014.t003
mean degree is higher for mitochondrial networks in NL cells as compared to their diseased counterparts. The microscopic rates \(C_2/C_1\) given by the simulations are also consistent with the above conclusions. With the exception of one example for AD and PD each, the normalized giant cluster \(N_g/N\) for all cases from our simulations also follows a consistent trend. For the two examples where \(N_g/N\) is slightly larger for NL cells than the diseased cells, we noticed that the overall mitochondrial network (network size in terms of the total number of edges in the cell) in the imaged area of the NL cells were significantly larger than those in the diseased cells. We suspect that this contributed to this discrepancy. Nevertheless, the mean degree in the same two examples is still consistent with our conclusions in the preceding paragraphs.

Despite the fact that the overall cumulative probability of the cluster sizes shifts to the left in all cases (see for example Fig 4A3 & 4B3), the different microscopic mechanisms for fragmentation lead to mitochondrial networks with significantly different fine structures. This is demonstrated by the fraction of X1, X2, and X3 species at steady state (Table 3, columns 4–9) obtained from simulations using C1 and C2 values for mitochondrial networks in cells with different pathologies and their respective control conditions. In the first group of conditions described above, the fraction of X3 species decreases significantly while X1 and X2 both increase moderately in the diseased state. This would lead to smaller and fewer cyclic loops. In the second group of diseases, X1 increases significantly while X2 decreases moderately. Since the propensity of \(X_1 + X_2 \rightarrow X_3\) reaction is given by \(a_1 \times X_1 \times X_2\), the relatively larger increase in X1 with the moderate decrease in X2 leads to a larger fraction of X3 species in the diseased conditions.
A larger increase in X3 and a smaller decrease in X2 would lead to a larger number of cyclic loops (although still smaller in sizes) and vice versa. The large variability in the fine structure of the mitochondrial network resulting from the different microscopic origins of fragmentation is highlighted further in Fig 5. We simulate mitochondrial networks in different diseases and their respective control conditions using their corresponding C1 and C2 values in the model, and extract the size distributions for branch lengths, cyclic loops, and clusters. The means of these distributions are shown in Fig 5, where the relative decrease vary significantly from one disease to another. A similar variability can also be seen in the variances of these three distributions while comparing different diseases to their respective control conditions (not shown).

Discussion
A tight balance between fission and fusion of mitochondria is crucial for the normal cell function [20, 29, 123]. This is probably why many degenerative diseases have been linked to the primary or secondary changes in mitochondrial dynamics leading to fragmented mitochondrial networks [9, 15–36]. Our analysis of images of mitochondrial networks from several previously reported experimental studies indicates that in general mitochondria in normal cells form a well-connected network that can be described by larger mean degree, giant cluster, branch lengths, clusters, and loops as compared to fragmented network characterized by smaller values of all these parameters in cells with nine different types of pathologies. We exploit these differences and model mitochondrial network to gain a quantitative understanding...
of the changes in the fission and fusion processes due to lateral and longitudinal interactions in all these pathologies.

It is worth mentioning that the class (transient versus complete) of fusion depends on the way two mitochondria interact with each other (see for example [83] for further details). Transient fusion where two mitochondria come into close apposition, remain fused for less than 4s to 5 min with a mean duration of 45s, and re-separate, preserving their original topologies, results from oblique or lateral interaction of two mitochondria associated with separate tracks. Complete fusion on the other hand results from longitudinal merging of organelles moving along a single track.

We show that the nine conditions can be divided into two main groups. The fragmentation in cells with AD, HD, DS, Ca$^{2+}$ overload, diabetes/cancer, and acute kidney injury pathologies mainly results from the decreased fusion in favor of fission due to lateral interaction between mitochondria. In case of OPA, PD, and ALS on the other hand, the balance between fusion and fission due to lateral interaction remains intact. However, the increased fission at the expense of fusion due to longitudinal interaction leads to fragmented mitochondrial network in these diseases.

The differences in the microscopic properties of mitochondrial fission and fusion could have key implications for the way fragmentation affects cell function depending on the morphology and the region of the cell where fragmentation occurs. For example, impaired balance between fission and fusion due to longitudinal interaction would lead to shorter linear chains of mitochondria that could significantly affect signaling along neuronal processes and synapses. Increased rate of fission at the expense of fusion due to lateral interaction on the other hand would likely have a more significant effect on the functions in regions such as cell body where a healthy mitochondrial network is key for the function of organelles such as nucleus and Golgi network.

We remark that our conclusions are based on limited data available. Consolidating these conclusions will need further future experiments and analysis of the mitochondrial networks in the different diseases using the approach discussed in this paper. Nevertheless, we believe that our framework provides a solid foundation for developing computational tools that could use these indicators for inferring the extent and types of signaling disruptions in different pathologies. While beyond the scope of this study, we believe that validating our predictions about the disruption of lateral and/or longitudinal fission/fusion in different diseases, experimental techniques similar to that used in Ref. [83] could be useful. In this technique, the exchange of matrix contents between individual mitochondria is visualized in real time as the two mitochondria fuse or detach by using mitochondrial matrix-targeted green-photoactivated, red-fluorescent Kindling fluorescent protein in combination with green or yellow fluorescence protein or the cyan-photoactivated mtPAGEP (mitochondria-targeted photoactivatable green-fluorescence protein) in combination with red fluorescence protein [83].

Supporting information
S1 Text. Description of different types of mitochondrial interactions, cell models, and diseases investigated in this study.

S1 Fig. Longitudinal and lateral mitochondrial interactions (fusion/fission). (a) End-to-end fusion of two mitochondria moving towards each other along a common microtubule (not shown), (b) Side-to-side and end-to-side fusion of two mitochondria moving on two different microtubule tracks (not shown). Arrows indicate the direction of motion.
S2 Fig. A smaller decrease in C2 leads to a smaller decrease in X3, and a smaller increase in X1 and X2, which would lead to a smaller but larger number of linear chains and larger number of cyclic loops. Here we compare mitochondrial network fragmentation in HD (striatal cells from mouse embryos bearing a 111 polyglutamine repeat Q111/0 and Q111/1) versus control [78] with C_{2u}/C_{2d} = 2.0 (top row) and diabetes (MitoNEET knockout mouse embryonic fibroblasts) versus control [65] with C_{2u}/C_{2d} = 1.8 (bottom row). Distributions of (a1) loop sizes, (a2) branch lengths, and (a3) cluster sizes (cumulative probability) for NL (red) and diseased cells (blue) from experimental images. (a4) Fraction of X1 (NL: green, diseased: red), X2 (NL: magenta, diseased: blue) and X3 (NL: black, diseased: cyan) species from the model as functions of the number of iterations using C1 and C2 values for HD experiments. The model results show average of 100 runs. (b1-b4) shows the same mitochondrial network features as (a1-a4) for MitoNEET knockout mouse embryonic fibroblasts with diabetes pathology and their normal counterparts.

(TIFF)

S3 Fig. A larger decrease in C1 leads to a significant decrease in the number of loops and branches. Here we compare mitochondrial network fragmentation in OPA (mouse embryonic fibroblasts with the pathogenic mutation R149W in human YME1L1) versus control [66] with C_{1u}/C_{1d} = 1.18 (top row) and PD (human primary skin fibroblasts obtained from sporadic late-onset PD patients) versus those from healthy age-matched control subjects [81] with C_{1u}/C_{1d} = 1.22 (bottom row). Distributions of (a1) loop sizes, (a2) branch lengths, and (a3) cluster sizes (cumulative probability) for NL (red) and diseased cells (blue) from experimental images. (a4) Fraction of X1 (NL: green, diseased: red), X2 (NL: magenta, diseased: blue) and X3 (NL: black, diseased: cyan) species from the model as functions of the number of iterations using C1 and C2 values for OPA experiments. The model results show average of 100 runs. (b1-b4) shows the same mitochondrial network features as (a1-a4) for human primary skin fibroblasts with PD pathology and their normal counterparts. Note that the curves for X3 species in diseased and normal cells overlap (a4, b4).

(TIFF)

S1 Table. Experimental micrographs processed in this study. Column 1 provides the disease, column 3 reports the cell/animal model, column 4 lists the condition for the experiment (normal versus diseased), and column 5 provides references where the images were originally published.

Abbreviations: WT-Wild type, KO-Knockout, NL-Normal, MEF-Mouse embryonic fibroblasts, HSF-Human skin fibroblasts, MEMN Mouse embryonic motor neurons, TM-YAC128 Transgenic mice Yeast Artificial Chromosome 128, HSF Human Skin Fibroblasts, RPTCs rat proximal tubular cells, RCA rat cortical astrocytes, CHCHD10—Coiled-coil helix-coiled-coil-helix domain-containing protein 10, YME1L1—Yeast mitochondrial escape 1-like 1 gene.

(DOCX)

S2 Table. Comparison of microscopic parameters of mitochondrial network obtained from simulations and experiments for additional cell/animal models or experimental conditions on AD, PD, and ALS diseases. Column 1 lists the condition for which images of normal (NL) and diseased cells were analyzed (column 2). Columns 3 & 4 and 5 & 6 compare <k> and N_g/N respectively from experiment and theory. Columns 7 & 8 are the C1 (tip-to-tip fusion/fission) and C2 (tip-to-side fusion/fission) values obtained by fitting the model to the data and used in simulations.

(DOCX)
Author Contributions

Conceptualization: Ghanim Ullah.
Data curation: Syed I. Shah, Johanna G. Paine, Carlos Perez, Ghanim Ullah.
Formal analysis: Syed I. Shah, Johanna G. Paine, Carlos Perez, Ghanim Ullah.
Funding acquisition: Ghanim Ullah.
Investigation: Syed I. Shah, Johanna G. Paine, Ghanim Ullah.
Methodology: Syed I. Shah, Johanna G. Paine, Ghanim Ullah.
Project administration: Ghanim Ullah.
Resources: Ghanim Ullah.
Software: Syed I. Shah, Johanna G. Paine, Carlos Perez, Ghanim Ullah.
Supervision: Ghanim Ullah.
Validation: Syed I. Shah, Johanna G. Paine, Carlos Perez, Ghanim Ullah.
Visualization: Syed I. Shah, Johanna G. Paine, Ghanim Ullah.
Writing – original draft: Syed I. Shah, Johanna G. Paine.
Writing – review & editing: Syed I. Shah, Ghanim Ullah.

References

1. Bakeeva L, Chentsov YS, Skulachev V. Mitochondrial framework (reticulum mitochondrial) in rat diaphragm muscle. Biochimica et Biophysica Acta (BBA)-Bioenergetics. 1978; 501(3):349–69.
2. Amchenkova AA, Bakeeva LE, Chentsov YS, Skulachev VP, Zorov DB. Coupling membranes as energy-transmitting cables. I. Filamentous mitochondria in fibroblasts and mitochondrial clusters in cardiomyocytes. The Journal of cell biology. 1988; 107(2):481–95. https://doi.org/10.1083/jcb.107.2.481 PMID: 3417757
3. Szabadkai G, Simoni AM, Rizzuto R. Mitochondrial Ca2+ uptake requires sustained Ca2+ release from the endoplasmic reticulum. Journal of Biological Chemistry. 2003; 278(17):15153–61. https://doi.org/10.1074/jbc.M300180200 PMID: 12586823
4. Anesti V, Scorrano L. The relationship between mitochondrial shape and function and the cytoskeleton. Biochimica et Biophysica Acta (BBA)-Bioenergetics. 2006; 1757(5–6):692–9.
5. Yang J-S, Kim J, Park S, Jeon J, Shin Y-E, Kim S. Mitochondrial Ca2+ uptake requires sustained Ca2+ release from the endoplasmic reticulum. Journal of Biological Chemistry. 2003; 278(17):15153–61. https://doi.org/10.1074/jbc.M300180200 PMID: 12586823
6. Collins TJ, Berridge MJ, Lipp P, Bootman MD. Mitochondria are morphologically and functionally heterogeneous within cells. Embo Journal. 2002; 21(7):1616–27. https://doi.org/10.1093/emboj/21.7.1616 WOS:000174992000012. PMID: 11927546
7. Collins TJ, Lipp P, Berridge MJ, Bootman MD. Mitochondria are morphologically and functionally heterogeneous within single cells. Journal of Physiology-London. 2002; 539:98p–9p. WOS:000174618200135.
8. Bereiterhahn J, Voth M. Dynamics of Mitochondria in Living Cells—Shape Changes, Dislocations, Fusion, and Fission of Mitochondria. Microscopy Research and Technique. 1994; 27(3):198–219. https://doi.org/10.1002/jemt.1070270303 WOS:A1994MV92300002. PMID: 8204911
9. Karbowski M, Youle R. Dynamics of mitochondrial morphology in healthy cells and during apoptosis. Cell death and differentiation. 2003; 10(8):870. https://doi.org/10.1038/sj.cdd.4401260 PMID: 12867994
10. Detmer SA, Chan DC. Functions and dysfunctions of mitochondrial dynamics. Nature reviews Molecular cell biology. 2007; 8(11):870. https://doi.org/10.1038/nrm2275 PMID: 17928812
11. Benard G, Bellance N, James D, Parrone P, Fernandez H, Letellier T, et al. Mitochondrial bioenergetics and structural network organization. Journal of cell science. 2007; 120(5):838–48.
12. Liao P-C, Tandarich LC, Hollenbeck PJ. ROS regulation of axonal mitochondrial transport is mediated by Ca2+ and JNK in Drosophila. PloS one. 2017; 12(5):e0178105. https://doi.org/10.1371/journal.pone.0178105 PMID: 28542430
13. Debattisti V, Gerencsér AA, Saotome M, Das S, Hajnóczky G. ROS control mitochondrial motility through p38 and the motor adaptor Miro/Trak. Cell reports. 2017; 21(6):1667–80. https://doi.org/10.1016/j.celrep.2017.10.060 PMID: 29117569

14. Deheshi S, Dabiri B, Fan S, Tsang M, Rintoul GL. Changes in mitochondrial morphology induced by calcium or rotenone in primary astrocytes occur predominantly through res-mediated remodeling. Journal of Neurochemistry. 2015; 133(5):684–99. https://doi.org/10.1111/jnc.13090 WOS:000353570500007. PMID: 25761412

15. Schon EA, Przedborski S. Mitochondria: the next (neurode) generation. Neuron. 2011; 70(6):1033–53. https://doi.org/10.1016/j.neuron.2011.06.003 PMID: 21689593

16. Smith EF, Shaw PJ, De Vos KJ. The role of mitochondria in amyotrophic lateral sclerosis. Neuroscience letters. 2017.

17. Guardia-Lagarita C, Area-Gomez E, Schon EA, Przedborski S. A new role for α-synuclein in Parkinson’s disease: Alteration of ER–mitochondrial communication. Movement Disorders. 2015; 30(8):1026–33. https://doi.org/10.1002/mds.26239 PMID: 25952565

18. Eisner V, Picard M, Hajnóczky G. Mitochondrial dynamics in adaptive and maladaptive cellular stress responses. Nature cell biology. 2018:1. https://doi.org/10.1038/s41556-017-0025-8

19. Bertholet A, Delerue T, Millet A, Moulis M, David C, Daloyau M, et al. Mitochondrial fusion/fission dynamics in neurodegeneration and neuronal plasticity. Neurobiology of disease. 2016; 90:3–19. https://doi.org/10.1016/j.nbd.2015.10.011 PMID: 26494254

20. Knott AB, Perkins G, Schwarzenbacher R, Bossy-Wetzel E. Mitochondrial fragmentation in neurodegeneration. Nature Reviews Neuroscience. 2008; 9(7):505. https://doi.org/10.1038/nrn2417 PMID: 18568013

21. Chen H, McCaffery JM, Chan DC. Mitochondrial fusion protects from neurodegeneration in the cerebellum. Cell. 2007; 130(3):548–62. https://doi.org/10.1016/j.cell.2007.06.026 PMID: 17693261

22. Hung CH-L, Cheng SS-Y, Cheung Y-T, Wuwongse S, Zhang NQ, Ho Y-S, et al. A reciprocal relationship between reactive oxygen species and mitochondrial dynamics in neurodegeneration. Redox biology. 2018; 14:7–19. https://doi.org/10.1016/j.redox.2017.08.010 PMID: 28837882

23. Youle RJ, Karbowski M. Mitochondrial fission in apoptosis. Nature reviews Molecular cell biology. 2005; 6(8):657. https://doi.org/10.1038/nrm1697 PMID: 16025099

24. Perfetti J-L, Roumier T, Kroemer G. Mitochondrial fusion and fission in the control of apoptosis. Trends in cell biology. 2005; 15(4):179–83. https://doi.org/10.1016/j.tcb.2005.02.005 PMID: 15817372

25. Manczak M, Calkins MJ, Reddy PH. Impaired mitochondrial dynamics and abnormal interaction of amyloid beta with mitochondrial protein Drp1 in neurons from patients with Alzheimer’s disease: implications for neuronal damage. Human molecular genetics. 2011; 20(13):2495–509. https://doi.org/10.1093/hmg/ddr139 PMID: 21459773

26. Wang X, Su B, Fujioka H, Zhu X. Dynamin-like protein 1 reduction underlies mitochondrial morphology and distribution abnormalities in fibroblasts from sporadic Alzheimer’s disease patients. The American journal of pathology. 2008; 173(2):470–82. https://doi.org/10.2353/ajpath.2008.071208 PMID: 18599615

27. Wang X, Su B, Siedlak SL, Moreira Pi, Fujioka H, Wang Y, et al. Amyloid-β overproduction causes abnormal mitochondrial dynamics via differential modulation of mitochondrial fission/fusion proteins. Proceedings of the National Academy of Sciences. 2008; 105(49):19318–23.

28. Wang X, Su B, Lee H-g, Li X, Perry G, Smith MA, et al. Impaired balance of mitochondrial fission and fusion in Alzheimer’s disease. Journal of Neuroscience. 2009; 29(28):9090–103. https://doi.org/10.1523/JNEUROSCI.1357-09.2009 PMID: 19605646

29. Selfridge JE, Lezi E, Lu J, Swerdlow RH. Role of mitochondrial homeostasis and dynamics in Alzheimer’s disease. Neurobiology of disease. 2013; 51:3–12. https://doi.org/10.1016/j.nbd.2011.12.057 PMID: 22266017

30. Hedskog L, Pinho CM, Filadi R, Rönnbäck A, Hertwig L, Wiehager B, et al. Modulation of the endoplasmic reticulum–mitochondria interface in Alzheimer’s disease and related models. Proceedings of the National Academy of Sciences. 2013;201300677.

31. Area-Gomez E, Schon EA. On the pathogenesis of Alzheimer’s disease: the MAM hypothesis. The FASEB Journal. 2017; 31(3):864–7. https://doi.org/10.1096/fj.20161309 PMID: 28246299

32. Aon MA, Cortassa S, Akar FG, Brown DA, Zhou L, O’Rourke B. From mitochondrial dynamics to arrhythmias. International Journal of Biochemistry & Cell Biology. 2009; 41(10):1940–8. https://doi.org/10.1016/j.biocel.2009.02.016 WOS:000270351100021. PMID: 19703656

33. Grandemange S, Herzig S, Martinou JC. Mitochondrial dynamics and cancer. Seminars in Cancer Biology. 2009; 19(1):50–6. https://doi.org/10.1016/j.semcancer.2008.12.001 WOS:000264608700008. PMID: 19138741
34. Su B, Wang XL, Zheng L, Perry G, Smith MA, Zhu XW. Abnormal mitochondrial dynamics and neurodegenerative diseases. Biochimica Et Biophysica Acta-Molecular Basis of Disease. 2010; 1802 (1):135–42. https://doi.org/10.1016/j.bbadis.2009.09.013 WOS:000273138500015. PMID: 19799998

35. Yoon Y, Galloway CA, Jhun BS, Yu TZ. Mitochondrial Dynamics in Diabetes. Antioxidants & Redox Signaling. 2011; 14(3):439–57. https://doi.org/10.1089/ars.2010.3286 WOS:000285876900010. PMID: 20518704

36. Zamponi E, Zamponi N, Coskun P, Quassollo G, Lorenzo A, Cannas SA, et al. Nrf2 stabilization prevents critical oxidative damage in Down syndrome cells. Aging Cell. 2018; 17(5). UNSP e12812 https://doi.org/10.1111/acel.12812 WOS:000445599100008.

37. Izzo A, Mollo N, Nitti M, Paladino S, Calì G, Genesio R, et al. Mitochondrial dysfunction in Down syndrome: molecular mechanisms and therapeutic targets. Molecular Medicine. 2018; 24(1):2. https://doi.org/10.1186/s10020-018-0004-y PMID: 30134785

38. Lin MT, Beal MF. Mitochondrial dysfunction and oxidative stress in neurodegenerative diseases. Nature. 2006; 443(7113):787. https://doi.org/10.1038/nature05292 PMID: 17051205

39. Sheng Z-H, Cai Q. Mitochondrial transport in neurons: impact on synaptic homeostasis and neurodegeneration. Nature Reviews Neuroscience. 2012; 13(2):77. https://doi.org/10.1038/nrn3156 PMID: 22218207

40. Westermann B. Bioenergetic role of mitochondrial fusion and fission. Biochimica et Biophysica Acta (BBA)-Bioenergetics. 2012; 1817(10):1833–8.

41. Olichon A, Baricault L, Gas N, Guillou E, Valette A, Belenguer P, et al. Loss of OPA1 perturbs the mitochondrial inner membrane structure and integrity, leading to cytochrome c release and apoptosis. Journal of Biological Chemistry. 2003; 278(10):7743–6. https://doi.org/10.1074/jbc.C200677200 PMID: 12509422

42. Chen H, Chan DC. Disruption of fusion results in mitochondrial heterogeneity and dysfunction. Journal of Biological Chemistry. 2009; 284(28):26185–92. https://doi.org/10.1074/jbc.M503062200 PMID: 19899901

43. Capaldi RA, Murray J, Byrne L, Janes MS, Marusich MF. Immunological approaches to the characterization and diagnosis of mitochondrial disease. Mitochondrion. 2004; 4(5):417–26.

44. Yu T, Robotham JL, Yoon Y. Increased production of reactive oxygen species in hyperglycemic conditions requires dynamic change of mitochondrial morphology. Proceedings of the National Academy of Sciences. 2006; 103(8):17451–6. https://doi.org/10.1073/pnas.0508262103 PMID: 16637731
55. Fang C, Bourdette D, Banker G. Oxidative stress inhibits axonal transport: implications for neurodegenerative diseases. Molecular neurodegeneration. 2012; 7(1):29.

56. Deheshi S, Dabiri B, Fan S, Tsang M, Rintoul GL. Changes in mitochondrial morphology induced by calcium or rotenone in primary astrocytes occur predominately through ROS-mediated remodeling. Journal of neurochemistry. 2015; 133(5):684–99. https://doi.org/10.1111/jn.13090 PMID: 25761412

57. Saotome M, Saffulina D, Szabadkai G, Das S, Fransson Å, Aspenstrom P, et al. Bidirectional Ca2+-dependent control of mitochondrial dynamics by the Miro GTPase. Proceedings of the National Academy of Sciences. 2008; 105(2):20728–33.

58. Jeyaraju DV, Cisbani G, Pellegrini L. Calcium regulation of mitochondria motility and morphology. Biochimica et Biophysica Acta (BBA)-Bioenergetics. 2009; 1787(1):1363–73.

59. Youle RJ, Van Der Bliek AM. Mitochondrial fission, fusion, and stress. 2012; 337 (6098):1062–5. https://doi.org/10.1126/science.1219855 PMID: 22936770

60. Mishra P, Chan DC. Metabolic regulation of mitochondrial dynamics. J Cell Biol. 2016; 212(4):379–87. https://doi.org/10.1083/jcb.201511036 PMID: 26858267

61. Zhao J, Zhang Y, Yang X, Guan J, Qin S, Guo Y, et al. Calcium-regulated mitochondrial dynamics. Biochimica et Biophysica Acta (BBA)-Molecular Cell Research. 2006; 1763(5–6):442–9.

62. Tan AR, Cai AY, Deheshi S, Dong Z. Regulation of mitochondrial dynamics by the Miro–Milton complex. The international journal of biochemistry & cell biology. 2009; 41(10):1972–6.

63. Brooks C, Wei Q, Cho S-G, Dong Z. Regulation of mitochondrial dynamics in acute kidney injury in cell culture and rodent models. The Journal of clinical investigation. 2009; 119(5):1275–85. https://doi.org/10.1016/j.jci.2009.04.021 PMID: 19349686

64. Molina AJ, Wikstrom JD, Stiles L, Las G, Mohamed H, Elovzer A, et al. Mitochondrial network protects beta cells from nutrient induced apoptosis. Diabetes. 2009.

65. Hartmann B, Wai T, Hu H, MacVicar T, Musante L, Fischer-Zirnsak B, et al. Homozygous YME1L1 mutation causes mitochondriopathy with optic atrophy and mitochondrial network fragmentation. Elife. 2016; 5:e16076. https://doi.org/10.7554/elife.16076 PMID: 27495975

66. Coskun PE, Busciglio J. Oxidative stress and mitochondrial dysfunction in Down’s syndrome: relevance to aging and dementia. Current gerontology and geriatrics research. 2012; 2012.

67. Helguera P, Seiglie J, Rodriguez J, Hanna M, Helguera G, Busciglio J. Adaptive downregulation of mitochondrial function in down syndrome. Cell metabolism. 2013; 17(1):132–40. https://doi.org/10.1016/j.cmet.2012.12.005 PMID: 23312288

68. Busciglio J, Yankner BA. Apoptosis and increased generation of reactive oxygen species in Down’s syndrome neurons in vitro. Nature. 1995; 378(6559):776. https://doi.org/10.1038/378776a0 PMID: 8524410

69. Jeyaraju DV, Cisbani G, Pellegrini L. Calcium regulation of mitochondria motility and morphology. Biochim et Biophys Acta (BBA)-Bioenergetics. 2009; 1787(1):1363–73.

70. Coskun PE, Busciglio J. Oxidative stress and mitochondrial dysfunction in Down’s syndrome: relevance to aging and dementia. Current gerontology and geriatrics research. 2012; 2012.

71. Helguera P, Seiglie J, Rodriguez J, Hanna M, Helguera G, Busciglio J. Adaptive downregulation of mitochondrial function in down syndrome. Cell metabolism. 2013; 17(1):132–40. https://doi.org/10.1016/j.cmet.2012.12.005 PMID: 23312288

72. Jeyaraju DV, Cisbani G, Pellegrini L. Calcium regulation of mitochondria motility and morphology. Biochim et Biophys Acta (BBA)-Bioenergetics. 2009; 1787(1):1363–73.

73. Youle RJ, Van Der Bliek AM. Mitochondrial fission, fusion, and stress. 2012; 337 (6098):1062–5. https://doi.org/10.1126/science.1219855 PMID: 22936770

74. Mishra P, Chan DC. Metabolic regulation of mitochondrial dynamics. J Cell Biol. 2016; 212(4):379–87. https://doi.org/10.1083/jcb.201511036 PMID: 26858267

75. Saotome M, Saffulina D, Szabadkai G, Das S, Fransson Å, Aspenstrom P, et al. Bidirectional Ca2+-dependent control of mitochondrial dynamics by the Miro GTPase. Proceedings of the National Academy of Sciences. 2008; 105(2):20728–33.

76. Jeyaraju DV, Cisbani G, Pellegrini L. Calcium regulation of mitochondria motility and morphology. Biochim et Biophys Acta (BBA)-Bioenergetics. 2009; 1787(1):1363–73.

77. Youle RJ, Van Der Bliek AM. Mitochondrial fission, fusion, and stress. 2012; 337 (6098):1062–5. https://doi.org/10.1126/science.1219855 PMID: 22936770

78. Mishra P, Chan DC. Metabolic regulation of mitochondrial dynamics. J Cell Biol. 2016; 212(4):379–87. https://doi.org/10.1083/jcb.201511036 PMID: 26858267

79. Saotome M, Saffulina D, Szabadkai G, Das S, Fransson Å, Aspenstrom P, et al. Bidirectional Ca2+-dependent control of mitochondrial dynamics by the Miro GTPase. Proceedings of the National Academy of Sciences. 2008; 105(2):20728–33.
77. Reis Y, Bernardo-Faura M, Richter D, Wolf T, Brors B, Hamacher-Brady A, et al. Multi-parametric analysis and modeling of relationships between mitochondrial morphology and apoptosis. PLoS One. 2012; 7(1):e28694. https://doi.org/10.1371/journal.pone.0028694 PMID: 22272225
78. Costa V, Giacomello M, Hudec R, Lopreiato R, Ermak G, Lim D, et al. Mitochondrial fission and cristae disruption increase the response of cell models of Huntington’s disease to apoptotic stimuli. EMBO molecular medicine. 2010; 2(12):490–503. https://doi.org/10.1002/emmm.201000102 PMID: 21069748
79. Wang XL, Su B, Siedlak SL, Moreira PI, Fujioka H, Wang Y, et al. Amyloid-beta overproduction causes abnormal mitochondrial dynamics via differential modulation of mitochondrial fission/fusion proteins. Proceedings of the National Academy of Sciences of the United States of America. 2008; 105(49):19318–23. https://doi.org/10.1073/pnas.0804871105 WOS:000261706000054. PMID: 19050078
80. Woo J-A, Liu T, Trotter C, Fang CC, De Navarre E, LePochale P, et al. Loss of function CHCHD10 mutations in cytoplasmic TDP-43 accumulation and synaptic integrity. Nature Communications. 2017; 8:15558. https://doi.org/10.1038/s41598-018-22090-x PMID: 29040422
81. Izzo A, Nitti M, Mollo N, Paladino S, Procaccini C, Faicchia D, et al. Metformin restores the mitochondrial network and reverses mitochondrial dysfunction in Down syndrome cells. Human molecular genetics. 2019; 28(6):1056–69. https://doi.org/10.1093/hmg/ddz016 PMID: 30428105
82. Gillespie DT. Exact Stochastic Simulation of Coupled Chemical-Reactions. Journal of Physical Chemistry. 1977; 81(25):2340–61. https://doi.org/10.1021/j100540a008 WOS:A1977EE49800008
83. Costa RO, Ferreiro E, Cardoso SM, Oliveira CR, Pereira CM. ER stress-mediated apoptotic pathway induced by Aβ peptide requires the presence of functional mitochondria. Journal of Alzheimer’s Disease. 2010; 20(2):625–36. https://doi.org/10.3233/JAD-2010-091369 PMID: 20182029
84. Zhang M, Xi Z, Zinman L, Bruni AC, Maletta RG, Curcio SA, et al. Mutation analysis of CHCHD10 in different neurodegenerative diseases. Brain. 2015; 138(8):e380–e.
85. Bannwarth S, Ait-El-Mkaadem S, Chaussemier A, Genin EC, Lacas-Gervais S, Fragaki K, et al. A mitochondrial origin for frontotemporal dementia and amyotrophic lateral sclerosis through CHCHD10 involvement. Brain. 2014; 137(8):2329–45.
86. Zhang M, Xi Z, Zinman L, Bruni AC, Maletta RG, Curcio SA, et al. Mutation analysis of CHCHD10 in different neurodegenerative diseases. Brain. 2015; 138(9):e380–e.
87. Janssens J, Van Broeckhoven C. Pathological mechanisms underlying TDP-43 driven neurodegeneration in FTLD–ALS spectrum disorders. Human molecular genetics. 2013; 22(R1):R77–R87. https://doi.org/10.1093/hmg/ddt349 PMID: 23900071
88. Wang W, Li L, Lin W-L, Dickson DW, Petrucelli L, Zhang T, et al. The ALS disease-associated mutant TDP-43 impairs mitochondrial dynamics and function in motor neurons. Human molecular genetics. 2013; 22(23):4706–19. https://doi.org/10.1093/hmg/ddt319 PMID: 23900071
89. Janssens J, Van Broeckhoven C. Pathological mechanisms underlying TDP-43 driven neurodegeneration in FTLD–ALS spectrum disorders. Human molecular genetics. 2013; 22(R1):R77–R87. https://doi.org/10.1093/hmg/ddt349 PMID: 23900071
90. Buratti E. Functional significance of TDP-43 mutations in disease. Advances in genetics. 91: Elsevier; 2015. p. 1–53. https://doi.org/10.1006/bs.adgen.2015.07.001 PMID: 26410029
91. Josephs KA, Whitwell JL, Tosakulwong N, Weigand SD, Murray ME, Liesinger AM, et al. TAR DNA-binding protein 43 and pathological subtype of Alzheimer’s disease impact clinical features. Annals of neurology. 2015; 78(5):697–709. https://doi.org/10.1002/ana.24493 PMID: 26224156
92. Wang W, Wang L, Lu J, Siedlak SL, Fujioka H, Liang J, et al. The inhibition of TDP-43 mitochondrial localization blocks its neuronal toxicity. Nature medicine. 2016; 22(8):869. https://doi.org/10.1038/nm.4130 PMID: 27348499
96. Zhang Y-J, Xu Y-F, Cook C, Gendron TF, Roettges P, Link CD, et al. Aberrant cleavage of TDP-43 enhances aggregation and cellular toxicity. Proceedings of the National Academy of Sciences. 2009; 106(18):7607–12.
97. Sohn Y-S, Tamir S, Song L, Michaeli D, Matouk I, Conlan AR, et al. NAF-1 and mitoNEET are central to human breast cancer proliferation by maintaining mitochondrial homeostasis and promoting tumor growth. Proceedings of the National Academy of Sciences. 2013; 110(36):14676–81.
98. Kusminski CM, Holland WL, Sun K, Park J, Spurgin SB, Lin Y, et al. MitoNEET-driven alterations in adipocyte mitochondrial activity reveal a crucial adaptive process that preserves insulin sensitivity in obesity. Nature medicine. 2012; 18(10):1539. https://doi.org/10.1038/nm.2899 PMID: 22961109
99. Kusminski CM, Chen S, Ye R, Sun K, Wang QA, Spurgin SB, et al. MitoNEET-Parkin effects in pancreatic α- and β-cells, cellular survival, and intrainsular cross talk. Diabetes. 2016; 65(6):1534–55. https://doi.org/10.2337/db15-1323 PMID: 26895793
100. Geldenhuys WJ, Leeper TC, Carroll RT. mitoNEET as a novel drug target for mitochondrial dysfunction. Drug discovery today. 2014; 19(10):1601–6. https://doi.org/10.1016/j.drudis.2014.05.001 PMID: 24814435
101. Vernay A, Marchetti A, Sabra A, Jauslin TN, Rosseli n M, Schere r PE, et al. MitoNEET- dependent formation of intermito chondrial junctions. Proceedings of the National Academy of Sciences. 2017; 114 (31):8277–82.
102. Berridge MJ. Calcium signalling remodelling and disease. Portland Press Limited, 2012.
103. Berridge MJ. Calcium signalling and neurodegenerative diseases. Trends in molecular medicine. 2009; 15(3):89–100. https://doi.org/10.1016/j.molmed.2009.01.001 PMID: 19230774
104. Lajdova I, Spustova V, Oksa A, Chorvatova A, Chorvat D Jr, Dzurik R. Intracellular calcium homeostasis in patients with early stages of chronic kidney disease: effects of vitamin D3 supplementation. Nephrology Dialysis Transplantation. 2009; 24(11):3376–81.
105. Heath H III, Lambert PW, Service FJ, Arnaud SB. Calcium homeostasis in diabetes mellitus. The Journal of Clinical Endocrinology & Metabolism. 1979; 49(3):462–6.
106. Ahn C, An B-S, Jeung E-B. Streptozotocin induces endoplasmic reticulum stress and apoptosis via disruption of calcium homeostasis in mouse pancreas. Molecular and cellular endocrinology. 2015; 412:302–8. https://doi.org/10.1016/j.mce.2015.05.017 PMID: 26003140
119. Kushnareva Y, Gerencser A, Bossy B, Ju W, White A, Waggoner J, et al. Loss of OPA1 disturbs cellular calcium homeostasis and sensitizes for excitotoxicity. Cell death and differentiation. 2013; 20(2):353. https://doi.org/10.1038/cdd.2012.128 PMID: 23138851

120. Ahn C, Kang J-H, Jeung E-B. Calcium homeostasis in diabetes mellitus. Journal of veterinary science. 2017; 18(3):261–6. https://doi.org/10.4142/jvs.2017.18.3.261 PMID: 28927245

121. Pérez MJ, Ponce DP, Osorio-Fuentelba C, Behrens MI, Quintanilla RA. Mitochondrial bioenergetics is altered in fibroblasts from patients with sporadic Alzheimer’s disease. Frontiers in neuroscience. 2017; 11:553. https://doi.org/10.3389/fnins.2017.00553 PMID: 29056898

122. Krebiehl G, Ruckerbauer S, Burbulla LF, Kieper N, Maurer B, Waak J, et al. Reduced basal autophagy and impaired mitochondrial dynamics due to loss of Parkinson’s disease-associated protein DJ-1. PloS one. 2010; 5(2):e9367. https://doi.org/10.1371/journal.pone.0009367 PMID: 20186336

123. Santel A. Get the balance right: mitofusins roles in health and disease. Biochimica et Biophysica Acta (BBA)-Molecular Cell Research. 2006; 1763(5–6):490–9.